Novavax Net Worth
Novavax Net Worth Breakdown | NVAX |
Novavax Net Worth Analysis
Novavax's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Novavax's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Novavax's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Novavax's net worth analysis. One common approach is to calculate Novavax's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Novavax's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Novavax's net worth. This approach calculates the present value of Novavax's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Novavax's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Novavax's net worth. This involves comparing Novavax's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Novavax's net worth relative to its peers.
Enterprise Value |
|
To determine if Novavax is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Novavax's net worth research are outlined below:
| Novavax had very high historical volatility over the last 90 days | |
| Novavax has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 983.71 M. Net Loss for the year was (545.06 M) with loss before overhead, payroll, taxes, and interest of (156.04 M). | |
| Novavax currently holds about 1.28 B in cash with (717.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Novavax has a frail financial position based on the latest SEC disclosures | |
| Roughly 57.0% of the company shares are owned by institutional investors | |
| Latest headline from zerohedge.com: COVID-19 Vaccine Protection Among Children Plummets Within Months CDC Study |
Novavax Quarterly Good Will |
|
Novavax uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Novavax. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Novavax's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Novavax's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Novavax is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Novavax backward and forwards among themselves. Novavax's institutional investor refers to the entity that pools money to purchase Novavax's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tsp Capital Management Group/llc | 2023-12-31 | 1.1 M | Jane Street Group, Llc | 2023-12-31 | 1.1 M | Northern Trust Corp | 2023-12-31 | 1 M | Bnp Paribas Arbitrage, Sa | 2023-12-31 | 861.5 K | Bank Of Montreal | 2023-12-31 | 855.8 K | Bmo Capital Markets Corp. | 2023-12-31 | 855.8 K | Barclays Plc | 2023-12-31 | 821.7 K | Charles Schwab Investment Management Inc | 2023-12-31 | 760.3 K | Allianz Asset Management Ag | 2023-12-31 | 634.7 K | State Street Corporation | 2023-12-31 | 16.8 M | Vanguard Group Inc | 2023-12-31 | 14.6 M |
Follow Novavax's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 572.41 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novavax's market, we take the total number of its shares issued and multiply it by Novavax's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Project Novavax's profitablity
Novavax's profitability indicators refer to fundamental financial ratios that showcase Novavax's ability to generate income relative to its revenue or operating costs. If, let's say, Novavax is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Novavax's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Novavax's profitability requires more research than a typical breakdown of Novavax's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.33) | |
| Return On Capital Employed | (1.88) | (1.79) | |
| Return On Assets | (0.29) | (0.31) | |
| Return On Equity | 0.76 | 1.30 |
When accessing Novavax's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Novavax's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Novavax's profitability and make more informed investment decisions.
The data published in Novavax's official financial statements usually reflect Novavax's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Novavax. For example, before you start analyzing numbers published by Novavax accountants, it's critical to develop an understanding of what Novavax's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Novavax's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Novavax's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Novavax's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Novavax. Please utilize our Beneish M Score to check the likelihood of Novavax's management manipulating its earnings.
Evaluate Novavax's management efficiency
Novavax has return on total asset (ROA) of (0.1702) % which means that it has lost $0.1702 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.982) %, meaning that it created substantial loss on money invested by shareholders. Novavax's management efficiency ratios could be used to measure how well Novavax manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 1.30 in 2024, whereas Return On Tangible Assets are likely to drop (0.33) in 2024. At this time, Novavax's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 747 M in 2024, whereas Other Current Assets are likely to drop slightly above 191.7 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (7.11) | (6.76) | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | (8.38) | (7.96) | |
| Enterprise Value Over EBITDA | (0.50) | (0.52) | |
| Price Book Value Ratio | (0.67) | (0.64) | |
| Enterprise Value Multiple | (0.50) | (0.52) | |
| Price Fair Value | (0.67) | (0.64) | |
| Enterprise Value | 209.5 M | 118.8 M |
The analysis of Novavax's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Novavax's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Novavax Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 0.4678 | Revenue 983.7 M | Quarterly Revenue Growth (0.18) | Revenue Per Share 9.762 | Return On Equity (8.98) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Novavax insiders, such as employees or executives, is commonly permitted as long as it does not rely on Novavax's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Novavax insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Novavax Corporate Filings
| 29th of April 2024 Other Reports | ViewVerify | |
8K | 26th of April 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 15th of April 2024 The schedule filed by any person or group who acquires beneficial ownership of more than 5% of a voting class of a company's equity securities registered under Section 12 of the Act | ViewVerify |
F4 | 12th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Novavax Earnings per Share Projection vs Actual
Be your own money manager
Our tools can tell you how much better you can do entering a position in Novavax without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Aroon Oscillator Now
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios |
| All Next | Launch Module |
Novavax Corporate Directors
Novavax corporate directors refer to members of a Novavax board of directors. The board of directors generally takes responsibility for the Novavax's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Novavax's board members must vote for the resolution. The Novavax board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Michael McManus | Independent Director | Profile | |
| Rachel King | Director | Profile | |
| Gary Evans | Independent Director | Profile | |
| Rajiv Modi | Director | Profile |
How to buy Novavax Stock?
The net worth of Novavax is the difference between its total assets and liabilities. Novavax's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Novavax's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Novavax's net worth can be used as a measure of its financial health and stability which can help investors to decide if Novavax is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Novavax stock.Already Invested in Novavax?
The danger of trading Novavax is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Novavax is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Novavax. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Novavax is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.41) | Revenue Per Share 9.762 | Quarterly Revenue Growth (0.18) | Return On Assets (0.17) | Return On Equity (8.98) |
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.